便细菌和短链脂肪酸在刺激性肠综合征:关系到亚型
Erica Sande Teige1,2, Eline Margrete Randulff Hillestad1,2, Elisabeth Kjelsvik Steinsvik2
1Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Neurogastroenterology and motility
|July 1, 2024
概括
与健康个体相比,刺激性肠综合征 (IBS) 患者的肠道细菌和短链脂肪酸 (SCFA) 水平发生变化. 这些变化可能会导致IBS亚型和症状.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 人类生理学 人类生理学
背景情况:
- 肠道微生物群在刺激性肠综合征 (IBS) 亚型中的作用尚不清楚.
- 调查便细菌,短链脂肪酸 (SCFA) 和IBS症状之间的关联至关重要.
研究的目的:
- 探索便细菌组成和与IBS亚型相关的SCFA水平的差异.
- 确定肠道微生物群变化与IBS症状严重程度之间的关系.
主要方法:
- 从IBS患者和健康对照组 (HCs) 收集了便样本和症状数据 (IBS-SSS,BSS,GSRS).
- 使用16S rRNA测序 (GA-map® Dysbiosis Test) 分析了便细菌的组成.
- 通过真空蒸和气体染色学量化SCFA.
主要成果:
- 与HC相比,IBS患者表现出更高的失生症频率,更低的动因细菌和更高的细菌.
- 八种细菌标记在IBS亚组和HC中显著不同.
- SCFA 和特定细菌与便秘,腹和整体症状严重程度的相关性较弱.
结论:
- 与HC相比,IBS患者表现出明显的便细菌组成.
- 在SCFA的变化与IBS亚型的发展有关.
相关概念视频
Irritable Bowel Syndrome I: Introduction
265
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
265
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
156
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
156
Chronic Bowel Disorders: Introduction
439
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
439
Drugs for Treatment of Constipation-Predominant IBS
154
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
154
Drugs for Treatment of Diarrhea-Predominant IBS
157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


